246 lines
56 KiB
HTML
246 lines
56 KiB
HTML
|
<!DOCTYPE html>
|
|||
|
|
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
|
|||
|
|
<meta charset="utf-8"/>
|
|||
|
|
<meta content="pandoc" name="generator"/>
|
|||
|
|
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
|
|||
|
|
<title>20 November, 2020</title>
|
|||
|
|
<style>
|
|||
|
|
code{white-space: pre-wrap;}
|
|||
|
|
span.smallcaps{font-variant: small-caps;}
|
|||
|
|
span.underline{text-decoration: underline;}
|
|||
|
|
div.column{display: inline-block; vertical-align: top; width: 50%;}
|
|||
|
|
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
|
|||
|
|
ul.task-list{list-style: none;}
|
|||
|
|
.display.math{display: block; text-align: center; margin: 0.5rem auto;}
|
|||
|
|
</style>
|
|||
|
|
<!--[if lt IE 9]>
|
|||
|
|
<script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
|
|||
|
|
<![endif]-->
|
|||
|
|
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
|||
|
|
<body>
|
|||
|
|
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
|
|||
|
|
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li><a href="#from-preprints">From Preprints</a></li>
|
|||
|
|
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
|
|||
|
|
<li><a href="#from-pubmed">From PubMed</a></li>
|
|||
|
|
<li><a href="#from-patent-search">From Patent Search</a></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li><strong>My home is my castle? The role of living arrangements on experiencing the COVID-19 pandemic in Germany</strong> -
|
|||
|
|
<div>
|
|||
|
|
The restrictions implemented to slow down the spread of COVID-19 are leading to noticeable declines in mental health. However, one’s living arrangement may buffer or catalyze the impact of COVID-19’s restrictions. We argue that restrictions may have a stronger impact for those with higher risk of loneliness and those who need to provide childcare. To test these considerations, we employ quantitative text analysis on open-ended questions from novel survey data of a sample of about 1,100 individuals. We examine how worries and loneliness vary across four different household structures: Living alone, shared living without children, living with a partner and children, and single parents. We find that individuals living alone are most likely to report feelings of loneliness, while single parents are at highest risk of experience care related worries, particularly regarding their financial situation. Those sharing a house, with or without children, had lower risks of experiencing both loneliness or care related worries. Implications for policy and practice are discussed.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/preprints/socarxiv/6c42q/" target="_blank">My home is my castle? The role of living arrangements on experiencing the COVID-19 pandemic in Germany</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Temporal Associations between Community Incidence of COVID-19 and Nursing Home Outbreaks in Ontario, Canada</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
The risk of nursing home COVID-19 outbreaks is strongly associated with the rate of infection in the communities surrounding homes, yet the temporal relationship between rising rates of community COVID-19 infection and the risk threshold for subsequent nursing home COVID-19 outbreaks is not well defined. This population-based cohort study included all COVID-19 cases in Canada9s most populous Province of Ontario between March 1-July 16, 2020. We evaluated the temporal relationship between trends in the number of active community COVID-19 cases and the number of nursing home outbreaks. We found that the average lag time between community cases and nursing home outbreaks was 23 days for Ontario overall, with substantial variability across geographic regions. We also determined thresholds of community incidence of COVID-19 associated with a 75% probability of observing a nursing home outbreak 5, 10 and 15 days into the future. For the province overall, when daily active COVID-19 community cases are 2.30 per 100,000 population, there is a 75% probability of a nursing home outbreak occurring five days later.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.17.20233312v1" target="_blank">Temporal Associations between Community Incidence of COVID-19 and Nursing Home Outbreaks in Ontario, Canada</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Predictive performance of international COVID-19 mortality forecasting models</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Forecasts and alternative scenarios of COVID-19 mortality have been critical inputs into a range of policies and decision-makers need information about predictive performance. We identified n=386 public COVID-19 forecasting models and included n=8 that were global in scope and provided public, date-versioned forecasts. For each, we examined the median absolute percent error (MAPE) compared to subsequently observed mortality trends, stratified by weeks of extrapolation, world region, and month of model estimation. Models were also assessed for ability to predict the timing of peak daily mortality. The MAPE among models released in July rose from 1.8% at one week of extrapolation to 24.6% at twelve weeks. The MAPE at six weeks were the highest in Sub-Saharan Africa (34.8%), and the lowest in high-income countries (6.3%). At the global level, several models had about 10% MAPE at six weeks, showing surprisingly good performance despite the complexities of modelling human behavioural responses and government interventions. The framework and publicly available codebase presented here (https://github.com/pyliu47/covidcompare) can be routinely used to compare predictions and evaluate predictive performance in an ongoing fashion.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.07.13.20151233v5" target="_blank">Predictive performance of international COVID-19 mortality forecasting models</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Early chains of transmission of COVID-19 in France</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Introduction: SARS-CoV-2, which causes COVID-19, has spread rapidly across the world. A dedicated surveillance system was implemented in France in January 2020 to improve early detection of cases and their contacts and limit secondary transmission. Our objective was to use contact-tracing data collected during this initial phase of the epidemic to better characterize SARS-CoV-2 transmission. Methods: We analyzed data collected during contact tracing and retrospective epidemiological investigations in France from 24 January to 30 March 2020. We assessed the secondary clinical attack rate and characterized the risk of a contact becoming a case. We described chains of transmission and estimated key parameters of spread. Results: Over the study period, 6,082 contacts of 735 confirmed cases were traced. The overall secondary clinical attack rate was 4.1% (95%CI 3.6-4.6) and increased with age of the index case and of the contact. Family contacts were at higher risk of becoming cases (adjusted odds ratio 2.1 (95%CI 1.4-3.0)) while nosocomial contacts were at lower risk (adjusted odds ratio 0.3 (95%CI 0.1-0.7)), compared to coworkers/friends. We identified 328 infector/infectee pairs, 49% of which were family members. The distribution of secondary cases was highly over-dispersed with 80% of secondary cases being caused by 10% of cases. The mean serial interval was 5.1 days (interquartile range 2-8 days) in contact-tracing pairs where late transmission events may be censored, and 6.8 (3-8) days in pairs investigated retrospectively. Conclusion: This study contributes to improving our knowledge of SARS-CoV-2 transmission, such as the importance of superspreading events. Contact-tracing data are challenging to collect but are key to better understand emerging pathogens.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.17.20232264v1" target="_blank">Early chains of transmission of COVID-19 in France</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Forecasting the spread of COVID19 in Hungary</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Time series analysis of the COVID19/ SARS-CoV-2 spread in Hungary is presented. Different methods effective for short-term forecasting are applied to the dataset, and predictions are made for the next 20 days. Autoregression and other exponential smoothing methods are applied to the dataset. SIR model is used and predicted 64% of the population could be infected by the virus considering the whole population is susceptible to be infectious Autoregression, and exponential smoothing methods indicated there would be more than a 60% increase in the cases in the coming 20 days. The doubling of the number of total cases is found to around 16 days using an effective reproduction number.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.19.20234815v1" target="_blank">Forecasting the spread of COVID19 in Hungary</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>A precise measure of the impact of the first wave of Covid-19 on life expectancy. Regional differentials in Switzerland</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Based on publicly available data supplied by the Swiss Federal Statistical Office (FSO), we calculated life tables by sex and by week for seven major regions of Switzerland in 2020, up to October 26th. These life tables provide information on the trends of life expectancy at birth and at the age of 65 years during the first wave of the coronavirus disease 2019 (COVID-19) epidemic. The results show a strong cyclical decrease in life expectancy, particularly in Ticino, where this variable has decreased by almost 6 years compared to the 2019 life expectancy, and in the Lake Geneva region. The other regions of Switzerland observed more modest decreases during the first wave, generally not exceeding a 2-year reduction. This decrease can be explained to some extent by seasonal variations in this indicator. In conclusion, the very sharp decrease in the average lifespan observed in the two regions mentioned above suggests that the first wave of the epidemic had a significant impact. It also reflects an unfavourable health situation. The life expectancy at the age of 65 years observed at the end of March 2020 in Ticino corresponded to the average life expectancy observed in Switzerland forty years ago. The calculated indicators have the advantage of accounting for the age structures of the respective populations. They therefore demonstrate their usefulness in monitoring during a pandemic, such as the one occurring currently.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.19.20234716v1" target="_blank">A precise measure of the impact of the first wave of Covid-19 on life expectancy. Regional differentials in Switzerland</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Antibodies to SARS-CoV-2 are associated with protection against reinfection</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Background It is critical to understand whether infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protects from subsequent reinfection. Methods We investigated the incidence of SARS-CoV-2 PCR-positive results in seropositive and seronegative healthcare workers (HCWs) attending asymptomatic and symptomatic staff testing at Oxford University Hospitals, UK. Baseline antibody status was determined using anti-spike and/or anti-nucleocapsid IgG assays and staff followed for up to 30 weeks. We used Poisson regression to estimate the relative incidence of PCR-positive results and new symptomatic infection by antibody status, accounting for age, gender and changes in incidence over time. Results A total of 12219 HCWs participated and had anti-spike IgG measured, 11052 were followed up after negative and 1246 after positive antibody results including 79 who seroconverted during follow up. 89 PCR-confirmed symptomatic infections occurred in seronegative individuals (0.46 cases per 10,000 days at risk) and no symptomatic infections in those with anti-spike antibodies. Additionally, 76 (0.40/10,000 days at risk) anti-spike IgG seronegative individuals had PCR-positive tests in asymptomatic screening, compared to 3 (0.21/10,000 days at risk) seropositive individuals. Overall, positive baseline anti-spike antibodies were associated with lower rates of PCR-positivity (with or without symptoms) (adjusted rate ratio 0.24 [95%CI 0.08-0.76, p=0.015]). Rate ratios were similar using anti-nucleocapsid IgG alone or combined with anti-spike IgG to determine baseline status. Conclusions Prior SARS-CoV-2 infection that generated antibody responses offered protection from reinfection for most people in the six months following infection. Further work is required to determine the long-term duration and correlates of post-infection immunity.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.18.20234369v1" target="_blank">Antibodies to SARS-CoV-2 are associated with protection against reinfection</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Predictors of adverse outcome in patients with suspected COVID-19 managed in a virtual hospital setting: a cohort study</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Objective: Identify predictors of adverse outcome in a Virtual Hospital (VH) setting for COVID 19. Design: Real-world prospective observational study. Setting: Virtual hospital remote assessment service in West Hertfordshire NHS Trust, UK. Participants: Patients with suspected COVID-19 illness enrolled directly from the community (post-accident and emergency (A&E) or medical intake assessment) or post-inpatient admission. Main outcome measure: Death or (re-)admission to inpatient hospital care over 28 days. Results: 900 patients with a clinical diagnosis of COVID-19 (455 referred from A&E or medical intake and 445 post-inpatient) were included in the analysis. 76 (8.4%) of these experienced an adverse outcome (15 deaths in admitted patients, 3 deaths in patients not admitted, and 58 additional inpatient admissions). Predictors of adverse outcome were increase in age (OR 1.04 [95%CI: 1.02, 1.06] per year of age), history of cancer (OR 2.87 [95%CI: 1.41, 5.82]), history of mental health problems (OR 1.76 [95%CI: 1.02, 3.04]), severely impaired renal function (OR for eGFR <30 = 9.09 [95%CI: 2.01, 41.09]) and having a positive SARS-CoV-2 PCR result (OR Mike Moo]). Conclusions: These predictors may help direct intensity of monitoring for patients with suspected or confirmed COVID-19 who are being remotely monitored by primary or secondary care services. Further research is needed to identify the reasons for increased risk of adverse outcome associated with cancer and mental health problems.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.09.20228189v2" target="_blank">Predictors of adverse outcome in patients with suspected COVID-19 managed in a virtual hospital setting: a cohort study</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Investigating placental pathologies in pregnant women with SARS-CoV-2: Systematic Review and Meta-analysis Protocol</strong> -
|
|||
|
|
<div>
|
|||
|
|
An investigation into placental pathology in pregnant women with SARS-CoV-2 has not yet been examined extensively; however, this knowledge would be beneficial in understanding the potential for vertical transmission of SARS-CoV-2 during pregnancy, via the placenta. Currently, results are conflicting, with some evidence suggesting rare placental infection. Conversely, compared to controls, one study determined that third trimester placentas were significantly more likely to show one feature of maternal vascular malperfusion (MVM), and intervillous thrombi, fetal vascular malperfusion or fetal vascular thrombosis, and increased perivillous fibrin deposition and intervillositis. In contrast, another study reported no significant differences in individual or group gross or microscopic pathological features. As well, no ACE2 expression has yet been detected in villous stroma, Hofbauer cells, or endothelial cells, and TMPRSS2 expression is only weakly present in villous endothelium. In light of the inconclusive evidence, the burden of placental pathologies potentially related to SARS-CoV-2 in pregnant women and their neonates or infants, remains at the forefront of medical attention, particularly among pathologists, and obstetricians worldwide. This protocol describes the steps of our systematic review, which aims to investigate differences in placental pathologies in pregnant women with SARS-CoV-2 versus pregnant women without the virus. Our study will identify case series, case-control and cohort studies of asymptomatic and symptomatic pregnant women, who test positive for SARS-CoV-2 during any stage of their pregnancy, as validated by laboratory confirmed positive antibody testing or using real-time reverse-transcriptase-polymerase chain reaction (rRT-PCR). Studies examining pregnant women who test positive during the first, second or third trimester, are eligible. Only articles written in English or French will be included. Literature reviews, systematic reviews, editorials, letters to the editor, conference abstracts, and commentaries will be excluded. The following databases will be searched: MEDLINE including Epub Ahead of Print, In-Process & Other Non-Indexed Citations (1946- November 17, 2020) and Embase (1980- November 17, 2020). Two specialized COVID-19 resources will also be searched November 18, 2020; Cochrane Covid-19 study register which indexes according to study design, and the WHO Covid-19 Collection which includes material from numerous sources including preprint servers. Primary outcomes of interest are: retroplacental hematoma, diffuse parenchymal consolidation, maternal vascular malperfusion, fetal vascular malperfusion, and other diseases of the placenta as detailed in this protocol. Observational studies will be assessed using the Ottawa-Newcastle scale. Data will be aggregated or synthesized at the level of individual participants. Tables will be used to summarize the general characteristics of the studies included. Depending on the data and the level of variation between studies, a meta-analysis will be used to synthesize data. Count and dichotomous data will be expressed as odds ratios with 95% confidence intervals, while continuous data will be expressed as a mean or standardized mean difference with 95% confidence intervals. Statistical heterogeneity of the included studies will be assessed using the I-squared test with 95% confidence intervals, and publication bias will be determined using a funnel plot and Egger’s test when possible (>10 included studies). This review will ultimately aid in informing pathologists, obstetricians, and gynecologists when managing and treating pregnant women with SARS-CoV-2. If no evidence of vertical transmission or changes to placenta can be elucidated, then this work can inform future research investigating alternate routes of SARS-CoV-2 transmission.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/e5tns/" target="_blank">Investigating placental pathologies in pregnant women with SARS-CoV-2: Systematic Review and Meta-analysis Protocol</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Social patterning and stability of COVID-19 vaccination acceptance in Scotland: Will those most at risk accept a vaccine?</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Vaccination is central to controlling COVID-19. Its success relies on having safe and effective vaccines and also on high levels of uptake by the public over time. Addressing questions of population-level acceptability, stability of acceptance and sub-population variation in acceptability are imperative. Using a prospective design, a repeated measures two-wave online survey was conducted to assess key sociodemographic variables and intention to accept a COVID-19 vaccine. The first survey (time 1) was completed by 3436 people during the period of national lockdown in Scotland and the second survey (n=2016) was completed two months later (time 2) when restrictions had been eased. At time one, 78% reported being willing to receive a COVID-19 vaccine. Logistic regression analyses showed that there were clear sociodemographic differences in intention to accept a vaccine for COVID-19 with intention being higher in participants of white ethnicity in comparison to Black, Asian, and minority ethnic (BAME) groups, and in those with higher income levels and higher education levels. Intention was also higher in those who were 9shielding9 due to underlying medical conditions. Our results suggest that future interventions such as mass media and social marketing need to be targeted to a range of sub-populations and diverse communities.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.19.20234682v1" target="_blank">Social patterning and stability of COVID-19 vaccination acceptance in Scotland: Will those most at risk accept a vaccine?</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape</strong> -
|
|||
|
|
<div>
|
|||
|
|
Zoonotic pandemics follow the spillover of animal viruses into highly susceptible human populations. Often, pandemics wane, becoming endemic pathogens. Sustained circulation requires evasion of protective immunity elicited by previous infections. The emergence of SARS-CoV-2 has initiated a global pandemic. Since coronaviruses have a lower substitution rate than other RNA viruses this gave hope that spike glycoprotein is an antigenically stable vaccine target. However, we describe an evolutionary pattern of recurrent deletions at four antigenic sites in the spike glycoprotein. Deletions abolish binding of a reported neutralizing antibody. Circulating SARS-CoV-2 variants are continually exploring genetic and antigenic space via deletion in individual patients and at global scales. In viruses where substitutions are relatively infrequent, deletions represent a mechanism to drive rapid evolution, potentially promoting antigenic drift.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2020.11.19.389916v1" target="_blank">Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>SARS-CoV-2 infection suppresses ACE2 function and antiviral immune response in the upper respiratory tract of infected patients</strong> -
|
|||
|
|
<div>
|
|||
|
|
There is an urgent need to elucidate the molecular mechanisms underlying the transmissibility and pathogenesis of SARS-CoV-2. ACE2 is a host ectopeptidase with well-described anti-inflammatory and tissue protective functions and the receptor for the virus. Understanding SARS-CoV-2-ACE2 interaction and the expression of antiviral host genes in early infection phase is crucial for fighting the pandemic. We tested the significance of soluble ACE2 enzymatic activity longitudinally in positive nasopharyngeal swabs at two time points after symptom consultation, along with gene expression profiles of ACE2, its proteases, ADAM17 and TMPRRS2, and interferon-stimulated genes (ISGs), DDX58, CXCL10 and IL-6. Soluble ACE2 activity decreased during infection course, in parallel to ACE2 gene expression. On the contrary, SARS-CoV-2 infection induced expression of the ISG genes in positive SARS-CoV-2 samples at baseline compared to negative control subjects, although this increase wanes with time. These changes positively correlated with viral load. Our results demonstrate the existence of mechanisms by which SARS-CoV-2 suppress ACE2 expression and function casting doubt on the IFN-induced upregulation of the receptor. Moreover, we show that initial intracellular viral sensing and subsequent ISG induction is also rapidly downregulated. Overall, our results offer new insights into ACE2 dynamics and inflammatory response in the human upper respiratory tract that may contribute to understand the early antiviral host response to SARS-CoV-2 infection.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2020.11.18.388850v1" target="_blank">SARS-CoV-2 infection suppresses ACE2 function and antiviral immune response in the upper respiratory tract of infected patients</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Conspiratorial thinking during COVID-19: The roles of paranoia, delusion-proneness, and intolerance to uncertainty</strong> -
|
|||
|
|
<div>
|
|||
|
|
The COVID-19 global pandemic has left many feeling a sense of profound uncertainty about their world, safety, and livelihood. Information that can help make sense of this uncertainty is offered by both official health-organizations as well as sources espousing misinformation and conspiracy theories. Individuals high in intolerance of uncertainty (IU) may be particularly impacted by the impoverished epistemic environment and may thus be more drawn to conspiratorial thinking (CT). In the present study we show that endorsement of COVID-19-specific conspiracy theories is associated with higher levels of intolerance of uncertainty as well as anxiety, delusion-proneness, and paranoid ideation. Furthermore, delusion-proneness and paranoia explained the relationship between IU and CT, and emerged as independent partial predictors of CT even when controlling for other facets of schizotypy. In contrast, anxiety did not explain the relationship between IU and CT, suggesting a stronger role of cognitive traits as opposed to affective factors. Overall, our findings highlight the importance of individual differences in IU, delusion proneness and paranoia in the development of CT in the context of the acute uncertainty of a global crisis, in which CT is more prevalent and salient. Informational intervention designs may benefit from leveraging the body of work demonstrating the efficacy of targeting IU to incite meaningful changes in thinking.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://psyarxiv.com/mb65f/" target="_blank">Conspiratorial thinking during COVID-19: The roles of paranoia, delusion-proneness, and intolerance to uncertainty</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Designing Efficient Contact Tracing Through Risk-Based Quarantining</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Contact tracing for COVID-19 is especially challenging because transmission often occurs in the absence of symptoms and because a purported 20% of cases cause 80% of infections, resulting in a small risk of infection for some contacts and a high risk for others. Here, we introduce risk-based quarantine, a system for contact tracing where each cluster (a group of individuals with a common source of exposure) is observed for symptoms when tracing begins, and clusters that do not display them are released from quarantine. We show that, under our assumptions, risk-based quarantine reduces the amount of quarantine time served by more than 30%, while achieving a reduction in transmission similar to standard contact tracing policies where all contacts are quarantined for two weeks. We compare our proposed risk-based quarantine approach against test-driven release policies, which fail to achieve a comparable level of transmission reduction due to the inability of tests to detect exposed people who are not yet infectious but will eventually become so. Additionally, test-based release policies are expensive, limiting their effectiveness in low-resource environments, whereas the costs imposed by risk-based quarantine are primarily in terms of labor and organization.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.11.16.20227389v2" target="_blank">Designing Efficient Contact Tracing Through Risk-Based Quarantining</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>COVID-19 symptoms at hospital admission vary with age and sex: ISARIC multinational study</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Background The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID 19. We present relationships of age, sex, and nationality to presenting symptoms. Methods International, prospective observational study of 60,109 hospitalized symptomatic patients with laboratory-confirmed COVID 19 recruited from 43 countries between 30 January and 3 August 2020. Logistic regression was performed to evaluate relationships of age and sex to published COVID 19 case definitions and the most commonly reported symptoms. Results 9Typical9 symptoms of fever (69%), cough (68%) and shortness of breath (66%) were the most commonly reported. 92% of patients experienced at least one of these. Prevalence of typical symptoms was greatest in 30- to 60-year-olds (respectively 80%, 79%, 69%; at least one 95%). They were reported less frequently in children (<=18 years: 69%, 48%, 23%; 85%), older adults (>=70 years: 61%, 62%, 65%; 90%), and women (66%, 66%, 64%; 90%; vs men 71%, 70%, 67%; 93%). The most common atypical presentations under 60 years of age were nausea and vomiting and abdominal pain, and over 60 years was confusion. Regression models showed significant differences in symptoms with sex, age and country. Interpretation Adults over 60 and children admitted to hospital with COVID 19 are less likely to present with typical symptoms. Nausea and vomiting are common atypical presentations under 30 years. Confusion is a frequent atypical presentation of COVID 19 in adults over 60 years. Women are less likely to experience typical symptoms than men.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.10.26.20219519v2" target="_blank">COVID-19 symptoms at hospital admission vary with age and sex: ISARIC multinational study</a>
|
|||
|
|
</div></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Drug: Nafamostat Mesilate<br/><b>Sponsor</b>: Chong Kun Dang Pharmaceutical<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: AZD7442; Drug: Placebo<br/><b>Sponsors</b>: AstraZeneca; QuintilesIMS<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: AZD7442; Drug: Placebo<br/><b>Sponsors</b>: AstraZeneca; QuintilesIMS<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: FSD201; Drug: Placebo<br/><b>Sponsor</b>: FSD Pharma, Inc.<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19 (PROVID-19)</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Dietary Supplement: Probiotics (2 strains 10x10^9 UFC); Dietary Supplement: Placebo (potato starch and magnesium stearate)<br/><b>Sponsors</b>: Centre de recherche du Centre hospitalier universitaire de Sherbrooke; Lallemand Health Solutions<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: COVI-VAC; Other: Placebo<br/><b>Sponsor</b>: Codagenix, Inc<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Other: Rehabilitation-focused program<br/><b>Sponsor</b>: VA Office of Research and Development<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>An Outpatient Study Investigating Non-prescription Treatments for COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Other: chlorine dioxide; Dietary Supplement: zinc acetate; Drug: Famotidine; Other: placebo; Dietary Supplement: lactoferrin, green tea extract<br/><b>Sponsor</b>: Profact, Inc.<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: LY3819253; Drug: LY3832479; Drug: Placebo<br/><b>Sponsors</b>: Eli Lilly and Company; AbCellera Biologics Inc.; Shanghai Junshi Bioscience Co., Ltd.<br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Drug: Nafamostat Mesilate<br/><b>Sponsor</b>: Chong Kun Dang Pharmaceutical<br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Early Versus Delayed Intubation of Patients With COVID-19</strong> - <b>Conditions</b>: COVID-19; Acute Hypoxemic Respiratory Failure<br/><b>Intervention</b>: Other: Endotracheal intubation<br/><b>Sponsor</b>: Evangelismos Hospital<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (CHO Cell)</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14; Biological: Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28; Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14; Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28; Biological: Two doses of placebo at the schedule of day 0, 14 #middle-dose group#; Biological: Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#; Biological: Two doses of placebo at the schedule of day 0, 14 #High-dose group#; Biological: Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#<br/><b>Sponsors</b>: Jiangsu Province Centers for Disease Control and Prevention; Academy of Military Medical Sciences，Academy of Military Sciences，PLA; ZHONGYIANKE Biotech Co, Ltd.; LIAONINGMAOKANGYUAN Biotech Co, Ltd<br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Effectiveness and Safety of Rhea Health Tone® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia</strong> - <b>Condition</b>: Covid19<br/><b>Intervention</b>: Dietary Supplement: Rhea Health Tone®<br/><b>Sponsors</b>: Universitas Padjadjaran; PT. Rhea Pharmaceutical Sciences Indonesia; Prodia Diacro Laboratories P.T.<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>BCG Vaccination to Prevent COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine; Drug: Preservative-free saline<br/><b>Sponsors</b>: Henry M. Jackson Foundation for the Advancement of Military Medicine; Harvard Medical School; Uniformed Services University of the Health Sciences; United States Department of Defense<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Intravenous Infusion of CAP-1002 in Patients With COVID-19</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Biological: CAP-1002; Biological: Placebo<br/><b>Sponsor</b>: Capricor Inc.<br/><b>Recruiting</b></p></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Pharmacological therapies against COVID-19 : state of the art, between hopes and disappointments</strong> - The COVID-19 outbreak has raised numerous attempts of diverse pharmacological interventions to improve the prognosis of the infection, especially among hospitalized patients due to an acute respiratory distress syndrome (ARDS). Initially, these interventions used known medications capable to directly target SARS-CoV-2 by investigating several antiviral therapies already applied with some success in other viral infections. Among them remdesivir appears to be the most promising drug against…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin</strong> - CONCLUSIONS: Overall, our findings demonstrate that AZ can exert broad-spectrum antiviral effects against IAV and SARS-CoV-2, and could be served as a potential clinical anti-SARS-CoV-2 drug in emergency as well as a promising lead compound for the development of next-generation anti-IAV drugs.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Potential inhibitors of SARS-CoV-2: Recent advances</strong> - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared in 2019 and is the causative agent of the new pandemic viral disease COVID-19. The outbreak of COVID-19 infection is affecting the entire world, thus many researchers and scientists are desperately looking for suitable vaccines and treatment options. Indeed, researches to find potential inhibitors of SARS-CoV-2 are mainly focused on targeting virus-host interactions or inhibiting viral assembly. Additionally, drugs and other…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Gender Disaggregation in COVID-19 and Increased Male Susceptibility</strong> - Novel coronavirus disease 2019 (COVID-19) is a growing public health crisis. Despite initial focus on the elderly population with comorbidities, it seems that large studies from the worst affected countries follow a sex-disaggregation pattern. Analysis of available data showed marked variations in reported cases between males and females among different countries with higher mortality in males. At this early stage of the pandemic, medical datasets at the individual level are not available;…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Remdesivir: A beacon of hope from Ebola virus disease to COVID-19</strong> - Since the emergence of coronavirus disease 2019 (Covid-19), many studies have been performed to characterize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and find the optimum way to combat this virus. After suggestions and assessments of several therapeutic options, remdesivir (GS-5734), a direct-acting antiviral drug previously tested against Ebola virus disease, was found to be moderately effective and probably safe for inhibiting SARS-CoV-2 replication. Finally, on 1 May 2020,…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction</strong> - No abstract</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Coronavirus and Its effect on the respiratory system: Is there any association between pneumonia and immune cells</strong> - CONCLUSION: The vaccine should receive further attention and in the long run, antiviral drugs and broad-spectrum vaccines are produced for infectious diseases.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site</strong> - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the pathogen that causes the disease COVID-19, produces replicase polyproteins 1a and 1ab that contain, respectively, 11 or 16 nonstructural proteins (nsp). Nsp5 is the main protease (M^(pro)) responsible for cleavage at eleven positions along these polyproteins, including at its own N- and C-terminal boundaries, representing essential processing events for subsequent viral assembly and maturation. We have determined X-ray…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Garlic (Allium sativum L.): a potential unique therapeutic food rich in organosulfur and flavonoid compounds to fight with COVID-19</strong> - Coronavirus disease 2019 (COVID-19) is the current major health crisis in the world. A successful strategy to combat the COVID-19 pandemic is the improvement of nutritional pattern. Garlic is one of the most efficient natural antibiotics against the wide spectrum of viruses and bacteria. Organosulfur (e.g., allicin and alliin) and flavonoid (e.g., quercetin) compounds are responsible for immunomodulatory effects of this healthy spice. The viral replication process is accelerated with the main…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV-2 Infection (COVID-19)</strong> - CONCLUSION: Inhibition of RBD-hACE2 interaction by different molecular scaffolds can be used as a preferred strategy for control of SARS-CoV-2 infection. Recently, published reports pointed out Lys31, Glu35 and Lys353 on B chain of ACE2 as crucial residues for mimicking and design of novel molecules as inhibitors SARS-CoV-2 attachment to human cells. Moreover, some recently identified RBD-hACE2 interaction inhibitors have also been described with their protein binding pattern and potencies (IC50…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome</strong> - Individuals with Down syndrome (DS; trisomy 21) display hyperactivation of interferon (IFN) signaling and chronic inflammation, which could potentially be explained by the extra copy of four IFN receptor (IFNR) genes encoded on chromosome 21. However, the clinical effects of IFN hyperactivity in DS remain undefined. Here, we report that a commonly used mouse model of DS overexpresses IFNR genes and shows hypersensitivity to IFN ligands in diverse immune cell types. When treated repeatedly with a…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>EGYVIR: An immunomodulatory herbal extract with potent antiviral activity against SARS-CoV-2</strong> - Due to the challenges for developing vaccines in devastating pandemic situations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developing and screening of novel antiviral agents are peremptorily demanded. Herein, we developed EGYVIR as a potent immunomodulatory herbal extract with promising antiviral activity against SARS-CoV-2. It constitutes of a combination of black pepper extract with curcumin extract. The antiviral effect of EGYVIR extract is attributed to the two key…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Histamine receptors and COVID-19</strong> - CONCLUSIONS: Clinical research into the potential benefits of H(2) receptor antagonists in managing COVID-19 inflammation began from a simple observation and now is being tested in multi-centre clinical trials. The positive effects of famotidine may be due to H(2) receptor-mediated immunomodulatory actions on mast cell histamine-cytokine cross-talk, rather than a direct action on SARS-CoV-2.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney</strong> - CONCLUSION: Our results indicate that neither hypertension nor antihypertensive treatment is likely to alter the expression of the key entry receptor for SARS-CoV-2 in the human kidney. Our data further suggest that in the absence of SARS-CoV-2 infection, kidney ACE2 is most likely nephro-protective but the age-related increase in its expression within lungs and kidneys may be relevant to the risk of SARS-CoV-2 infection.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Investigation of CD26, a potential SARS2-CoV-2 receptor, as a biomarker of age and pathology</strong> - CONCLUSIONS: These findings may explain the heterogeneity of SARS-CoV-2 infection, high serum sCD26 levels may protect from viral infection by competively inhibiting the virus binding to cellular CD26, whereas low sCD26 levels could increase the risk of infection. Measuring serum sCD26 level may help to identify individuals at high risk for the COVID-19 infection.</p></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>AN EFFICIENT METHODOLOGY TO MANAGE THE ADMISSIONS IN HOSPITALS DURING THE PANDEMICS SUCH AS COVID 19</strong> -</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SARS-CoV-2 예방을 위한 mRNA기반 항원보강제 혼합물 합성 방법</strong> - 본 발명은 SARS-CoV-2(코로나 바이러스) 예방을 위한 mRNA 항원보강제에 관한 것으로 코로나 바이러스에 대한 백신으로서 상기의 항원에 대한 예방을 목적으로 하고 있다. 아이디어에는 보강제에 해당하는 완전프로인트항원보강제(CFA)와 불완전프로인트항원보강제(IFA), 번역과 안정성의 최적화가 된 mRNA, mRNA 운반체, 양이온성 지질 나노입자(lipid nanoparticles)로 구성되며 기존의 백신에 비해 효율성과 안정성의 측면에서 더 향상된 효과를 가지고 있다.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vorrichtung zum Reinigen und/oder Desinfizieren von Objekten</strong> -</p>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Vorrichtung (1) zum Desinfizieren von Objekten mit einer Basiseinheit (2), mit einem Aufnahmebehälter (4) für Wasser, welcher an der Basiseinheit (2) montierbar und von der Basiseinheit demontierbar ist, mit einer Objekthalterung (6) zum Halten und/oder Stützen der Objekte (10), wobei diese Objekthalterung (6) in dem Aufnahmebehälter montierbar ist und mit einer elektrisch betriebenen Reinigungseinrichtung (8), welche in dem Wasser befindliche Objekte zumindest mittelbar reinigt oder desinfiziert, wobei diese Reinigungseinrichtung in der Basiseinheit befindliche Erzeugungsmittel zum Erzeugen einer elektrischen Spannung aufweist sowie einen Plasmagenerator und/oder eine Ultraschallerzeugungseinheit.</p></li>
|
|||
|
|
</ul>
|
|||
|
|
<img alt="embedded image" id="EMI-D00000"/>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Methods for treating Arenaviridae and Coronaviridae virus infections</strong> - Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I:</li>
|
|||
|
|
</ul>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">wherein the ’ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.</p>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Atemschutz-Baukastensystem</strong> -
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Atemschutz-Baukastensystem, das aufweist:</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">eine auf zumindest Mund und Nase einer Person aufsetzbare Maske (1), die einen Eingang (11) und einen Ausgang (12) aufweist, und</li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">mindestens einen Schlauch (3, 31, 32),</li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">wobei sämtliche Komponenten des Atemschutz-Baukastensystems modular ausgebildet und über Steckverbindungen oder Schraubverbindungen (115, 125, 155, 165, 175, 215, 315, 75, 915) miteinander verbindbar sind, um der Maske (1) Luft über deren Eingang (11) zuzuführen und/oder ausgeatmete Luft vom Ausgang (12) der Maske (1) wegzuführen.</li>
|
|||
|
|
</ul>
|
|||
|
|
<img alt="embedded image" id="EMI-D00000"/>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vorrichtung zur Übergabe und Dekontamination von mit Krankheitserregern kontaminierten Gegenständen oder Erzeugnissen</strong> -
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Vorrichtung zur Übergabe von mit Krankheitserregern kontaminierten Gegenständen oder Erzeugnissen nach einer Dekontamination, umfassend eine Einrichtung zur Dekontamination der mit Krankheitserregern kontaminierten Gegenstände oder Erzeugnisse mit mindestens einer UV-Strahlungsquelle (24), eine Durchzugseinrichtung mit Ein- und/oder Ausgabebereichen für die kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse, dadurch gekennzeichnet, dass die Durchzugseinrichtung im Eingang bzw. im Ausgang zum Ein- und/oder Ausgabebereich angeordnete sich paarweise gegenüberliegende Walzen (17) und Räder (4) umfasst, die zum Einzug bzw. zur Ausgabe der kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse vorgesehen sind, wobei die Walzen (17) und die Räder (4) durch im Ein- und/oder Ausgabebereich angeordnete Sensoren (23) und einer elektronische Kontrolleinheit (27) in Bewegung bringbar sind, wobei die Gegenstände oder Erzeugnisse in den Bereich der Einrichtung zur Dekontamination förderbar sind, der zwischen den paarweise angeordneten Walzen (17) und Rädern (4) vorgesehen ist, welcher sich gegenüberliegende Platten (25) aus Quarzglas oder einem UV-transparenten Polymermaterial, wie Graphen oder Kunstglas umfasst, über bzw. unter welchen die UV-Strahlungsquelle (24) angeordnet ist, welche als UVC-LED-Leiste und/oder Modul mit mindestens einer LED-Lampe ausgebildet ist.</p></li>
|
|||
|
|
</ul>
|
|||
|
|
<img alt="embedded image" id="EMI-D00000"/>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물</strong> - 본 발명은 화학식 1로 표시되는 화합물, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환 예방 또는 치료용 약학적 조성물을 제공한다. [화학식 1] .</p>
|
|||
|
|
<pre><code> JPEG
|
|||
|
|
112020094463686-pat00017.jpg
|
|||
|
|
48
|
|||
|
|
135</code></pre></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>新型冠状病毒中和性抗体滴度检测ELISA试剂盒</strong> - 本发明提供一种新型冠状病毒中和性抗体滴度检测ELISA试剂盒，其中包括：包被有生物素‑链霉亲和素标记的人ACE2蛋白的酶标板、辣根过氧化酶标记的新型冠状病毒RBD蛋白、新型冠状病毒中和性抗体阳性对照、包被液、洗涤液、稀释液、封闭液、显色液和终止液等。该试剂盒具有成本低，操作简单，高灵敏度、高特异性、高准确度的特点，可用于新型冠状病毒中和抗体的批量、快速检测。</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Reagenzien und Verwendungen zur Diagnose einer SARS-CoV-2-Infektion</strong> -</p>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
</p><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">Diagnostisch nützlicher Träger umfassend ein Polypeptid umfassend SEQ ID NO1 oder eine Variante davon, die an einen Antikörper gegen SEQ ID NO1 aus einer Probe von einem Patienten binden kann, der an einer SARS-CoV-2-Infektion leidet, wobei das Polypeptid bevorzugt auf der Festphase des Trägers immobilisiert ist.</p></li>
|
|||
|
|
</ul>
|
|||
|
|
<img alt="embedded image" id="EMI-D00000"/>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Reagenzien und Verwendungen zur Diagnose einer SARS-CoV-2-Infektion</strong> -
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Verwendung eines Polypeptides umfassend SEQ ID NO1 oder eine Variante davon, die an einen Antikörper gegen SED ID NO1 aus einer Probe von einem Patienten binden kann, zur Herstellung eines diagnostischen Kits.</p></li>
|
|||
|
|
</ul>
|
|||
|
|
<img alt="embedded image" id="EMI-D00000"/>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
|||
|
|
|
|||
|
|
|
|||
|
|
<script>AOS.init();</script></body></html>
|